HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology: Data From the Baseline Phase of the Onclarity Trial.

Conclusions: Onclarity is clinically validated for cotesting in NILM women. Genotyping actionably stratifies women at greater CIN3 or higher risk. PMID: 30649177 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30649177?dopt=Abstract

Source: American Journal of Clinical Pathology - January 14, 2019 Category: Pathology Authors: Stoler MH, Wright TC, Parvu V, Yanson K, Eckert K, Kodsi S, Cooper C Tags: Am J Clin Pathol Source Type: research